EFLORNITHINE MARKET

INTRODUCTION TOEFLORNITHINE MARKET

Eflornithine is a drug used to treat African trypanosomiasis and excessive facial hair development in women. It is marketed under the trade names Vaniqa and others. It is specifically used in conjunction with nifurtimox to treat the second stage of sleeping sickness brought on by T. b. gambiense.

Women who have undesired facial hair, typically around the lips or under the chin, might use eflornithine to prevent it from growing out too quickly. Eflornithine works by inhibiting a naturally occurring chemical found in your hair follicle that is required for hair growth (the sac where each hair grows).

Women can eliminate undesirable facial hair using eflornithine topical treatment. Topical eflornithine does not stop hair growth or eradicate face hair permanently. 

EFLORNITHINE MARKET SIZE AND FORECAST

The Global EFLORNITHINE market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

EFLORNITHINE MARKETNEW PRODUCT LAUNCH

Vaniqa is introduced to the OB/GYN community by Women First HealthCare. Women First HealthCare, Inc. (Nasdaq:WFHC), a specialty pharmaceutical firm, said today that it has started marketing Vaniqa(R) (eflornithine hydrochloride) Cream, 13.9%, its newest product, to the OB/GYN market.

A joint venture between Bristol-Myers Squibb and Gillette provided Women First with Vaniqa(R), a topical lotion that has been clinically shown to decrease the growth of undesirable facial hair in women.

Vaniqa(R) is promotion-sensitive, and market research conducted by the previous owners of Vaniqa(R) revealed that the medicine should be advertised to both gynaecologists and dermatologists.

Previous prescription trends demonstrate this. Through this launch, we will be able to promote to the OB/GYNs that we already contact and take advantage of their existing connections while incurring little additional cost.

It is recommended for ladies to take Vaniqa(R) to get rid of unsightly facial hair. In both non-clinical and clinical tests, vaniqa has been found to slow the rate of hair growth. Only the face and nearby afflicted areas beneath the chin of affected people have been investigated when using vaniqa.

Use ought to be restricted to these domains. For approximately 60% of the women who used Vaniqa in controlled trials, there was a clinically meaningful and statistically significant improvement in the reduction of facial hair development around the lips and under the chin.

Vaniqa does not remove hair; rather, it works in conjunction with other popular hair removal techniques like electrolysis, shaving, depilatory creams, waxing, and tweezing. In addition to Vaniqa, the patient should continue to employ hair removal methods as necessary.

EFLORNITHINE MARKETCOMPANY PROFILE

• Women First Healthcare
• PubMed
• Bio-Labs
• SkinMedica
• Bristol-Myers Squibb

THIS REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many EFLORNITHINE are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global EFLORNITHINE and key vendor selection criteria
3. Where is the EFLORNITHINE manufactured? What is the average margin per unit?
4. Market share of Global EFLORNITHINE market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global EFLORNITHINE in-house
6. key predictions for next 5 years in Global EFLORNITHINE market
7. Average B-2-B EFLORNITHINE market price in all segments
8. Latest trends in EFLORNITHINE market, by every market segment
9. The market size (both volume and value) of the EFLORNITHINE market in 2024-2030 and every year in between?
10. Production breakup of EFLORNITHINE  market, by suppliers and their OEM relationship